Evidence map›Paper›PMID 36063402›Full record

ArticleThe Prostate2023

Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.

Madhav Kc, Evrim Oral, Ariane L Rung, Edward Trapido, Laura S Rozek, Elizabeth T H Fontham, Jeannette T Bensen, Laura Farnan, Susan E Steck, Lixin Song and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in The Prostate, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Madhav KcCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, Connecticut, USA.ORCID 0000-0002-4659-4348
Evrim OralBiostatistics Program, School of Public Health, Louisiana State University Health Sciences Center-New Orleans, New Orleans, Louisiana, USA.
Ariane L RungEpidemiology Program, School of Public Health, Louisiana State University Health Sciences Center-New Orleans, New Orleans, Louisiana, USA.
Edward TrapidoEpidemiology Program, School of Public Health, Louisiana State University Health Sciences Center-New Orleans, New Orleans, Louisiana, USA.
Laura S RozekDepartment of Environmental Health Sciences, University of Michigan School of Public Health, Ann Arbor, Michigan, USA.
Elizabeth T H FonthamEpidemiology Program, School of Public Health, Louisiana State University Health Sciences Center-New Orleans, New Orleans, Louisiana, USA.
Jeannette T BensenDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Laura FarnanDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Susan E SteckDepartment of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.
Lixin SongLineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
James L MohlerDepartment of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.ORCID 0000-0002-7726-3795
Saira KhanEpidemiology Program, College of Health Sciences, University of Delaware, Newark, Delaware, USA.ORCID 0000-0002-9024-9461
Sanah VohraDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Edward S PetersEpidemiology Program, School of Public Health, Louisiana State University Health Sciences Center-New Orleans, New Orleans, Louisiana, USA.ORCID 0000-0003-4928-6532
Louisiana State University Health Sciences Center New Orleans · USUniversity of North Carolina at Chapel Hill · USDepartment of Behavioral Health · USNebraska Medical Center · USRoswell Park Comprehensive Cancer Center · USUniversity of Michigan · USUniversity of South Carolina · USYale Cancer Center · US

Funding

Department of Defense W81XWH-17-1-0119U.S. Department of Defense DAMD 17-03-2-0052
6 · The paper itself

Abstract

introductionFinancial toxicity (FT) is a growing concern among cancer survivors that adversely affects the quality of life and survival. Individuals diagnosed with aggressive cancers are often at a greater risk of experiencing FT. The objectives of this study were to estimate FT among prostate cancer (PCa) survivors after 10-15 years of diagnosis, assess the relationship between PCa aggressiveness at diagnosis and FT, and examine whether current cancer treatment status mediates the relationship between PCa aggressiveness and FT.

methodsPCa patients enrolled in the North Carolina-Louisiana Prostate Cancer Project (PCaP) were recontacted for long-term follow-up. The prevalence of FT in the PCaP cohort was estimated. FT was estimated using the COmprehensive Score for Financial Toxicity, a validated measure of FT. The direct effect of PCa aggressiveness and an indirect effect through current cancer treatment on FT was examined using causal mediation analysis.

resultsMore than one-third of PCa patients reported experiencing FT. PCa aggressiveness was significantly independently associated with high FT; high aggressive PCa at diagnosis had more than twice the risk of experiencing FT than those with low or intermediate aggressive PCa (adjusted odds ratio [aOR] = 2.13, 95% CI = 1.14-3.96). The proportion of the effect of PCa aggressiveness on FT, mediated by treatment status, was 10%, however, the adjusted odds ratio did not indicate significant evidence of mediation by treatment status (aOR = 1.05, 95% CI = 0.95-1.20).

conclusionsAggressive PCa was associated with high FT. Future studies should collect more information about the characteristics of men with high FT and identify additional risk factors of FT.

Indexed as

Financial StressProstatic NeoplasmsQuality of LifeHumansLouisianaMaleNorth CarolinaCancer aggressivenessCancer treatmentfinancial toxicityMediation analysisNC-LA PCaPProstate cancer

Identifiers

PMID36063402
PMCPMC10087487
OpenAlexW4294636629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.